GHGeorgia E. Hume

Georgia E. Hume

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Georgia E. Hume has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • D Lincoln

    Cancer & Population Studies, Queensland Institute of Medical Research, Brisbane

    2 shared publications
  • D Templeton

    Department of Gastroenterology, Royal Brisbane & Women’s Hospital, Brisbane

    2 shared publications
  • Elizabeth V. Fowler

    QIMR Berghofer Medical Research Institute and University of Queensland School of Medicine, Herston Campus, Brisbane, Australia

    2 shared publications
  • G L Radford-Smith

    Department of Gastroenterology, Royal Brisbane & Women’s Hospital, Brisbane

    2 shared publications
  • Graham L Radford-Smith

    2 shared publications
  • Graham L. Radford-Smith

    QIMR Berghofer Medical Research Institute and University of Queensland School of Medicine, Herston Campus;Department of Gastroenterology, Royal Brisbane and Women's Hospital, Brisbane, Australia

    2 shared publications

Latest Publications

  • The need for better preventative strategies for inflammatory bowel disease patients at risk of herpes zoster virus

    by William A. Bye, Miles P. Sparrow, Susan J. Connor, Jane M. Andrews, Katie Ellard, Watson Ng, Georgia Hume, Sally Antoniades, Alissa J. Walsh

    Background: Immunosuppressed inflammatory bowel disease (IBD) patients have an increased risk of herpes zoster virus (HZV) infection. The existing live‐attenuated HZV vaccine is contraindicated in some of these patients and can only be used with caution in others.Aims: To describe characteristics of IBD patients suffering HZV to enable implementation of risk mitigation strategies for those at highest risk.Methods: Gastroenterologists completed a proforma for IBD patients who experienced HZV infection: IBD phenotype, details of HZV infection, immunosuppression and any change to treatment upon diagnosis of HZV.Results: A total of 30 cases was identified: Crohn disease (CD) (n = 25) and ulcerative colitis (n = 5). In total, 80% (20/25) of the CD patients had penetrating, stricturing or perianal disease. Time from commencement of immunosuppression to HZV infection was highly variable (range: 3 months to over 10 years). A total of 90% (27/30) of patients was on at least one immunosuppressive therapy; of those, one‐third was on monotherapy (9/27) and two‐thirds (18/27) on dual therapy. A total of 89% (24/27) of immunosupressed patients was on a thiopurine (monotherapy; 6/27) or in combination (18/27). Complications of HZV occurred in 27% (8/30) of patients.Conclusion: Our series is consistent with existing epidemiological analysis that identified more severe IBD and the use of multiple immunosuppressive therapies as risk factors for HZV. If the promise of an investigational subunit HZV vaccine is realised in immunocompromised patients, better protection may be possible in the future. Thiopurine medications were the most commonly used immunosuppressant in this series. Age and duration of immunosuppressive therapy do not appear to predict HZV infection.


  • Open Access

    Altered Expression of Angiotensinogen and Mediators of Angiogenesis in Ileal Crohn’s Disease

    by Georgia E. Hume, James D. Doecke, Ning Huang, Elizabeth V. Fowler, Ian S. Brown, Lisa A. Simms, Graham L. Radford-Smith

    Background & Aims: Angiotensin II (AII) is a powerful splanchnic vasoconstrictor with pro-inflammatory and pro-fibrotic properties. Angiotensin converting enzyme (ACE) inhibitors and AII Receptor Antagonists (ARBs) are therapeutic in animal models of colitis. The aim of this case-control study is to determine the expression of angiotensinogen and related genes in human ileal Crohn’s disease. Methods: Using quantitative real-time polymerase chain reaction (RT-PCR), we measured mRNA expression levels of angiotensinogen (AGT), hypoxia inducible factor (HIF)1α and melanoma cell adhesion molecule (MCAM; CD146) in 101 human samples (69 biopsy, 12 resection) from affected ileum (inflamed CD cases, n=36) and unaffected ileum (non-inflamed CD cases, n=45 and controls, n=20). Immunohistochemistry for angiotensinogen was also performed. The study was of case-control design in a tertiary care setting. Results: Ileal expression of AGT was lower in CD cases compared to controls (p<0.0001), in inflamed CD samples (p=0.017) and current smokers (p=0.02). HIF1α expression was lower in non-inflamed CD biopsy samples than controls (p=0.006). The presence of disease-associated NOD2 variants was associated with increased expression of markers of angiogenesis (HIF1α p=0.009; MCAM p=0.007) in inflamed CD samples. Angiotensinogen immunohistochemical staining supported the quantitative RT-PCR expression findings. Conclusions: Angiotensinogen expression is down regulated in human ileal CD, particularly in the presence of inflammation and current cigarette smoking, implicating the mesenteric vasculature and mucosal hypoxia as co-factors in ileal CD pathogenesis. A novel reduction in HIF1α expression in non-inflamed ileal mucosa in CD patients was also demonstrated.. Abbrevations: AI: angiotensin I; AII: angiotensin II; ACE: Angiotensin Converting Enzyme; AGT: angiotensinogen; ARB: Angiotensin II receptor Antagonists; AT1: Angiotensin type 1; AT2: Angiotensin type 2: AT-6: Angiotensinogen-6; ATG16L1: Autophagy-related 16-like 1; CD: Crohn’s disease; CTGF: Connective Tissue Growth Factor; ECM: Extracellular matrix; HIF-1: Hypoxia inducible factor-1; IBD: Inflammatory Bowel Disease; IBDU: Inflammatory Bowel Disease, type unclassified; MCAM: Melanoma Cell Adhesion Molecule; mRNA: Messenger RNA; NOD: Nucleotide-binding oligomerisation domain; NF-κB: Nuclear Factor-κB; NSAIDs: Non-Steroidal Anti-Inflammatory Drugs; PCR: Polymerase Chain Reaction; RAAS: Renin-angiotensin-aldosterone system; RT-PCR: Real Time Polymerase Chain Reaction; SNP: Single Nucleotide Polymorphism; TGF-β: Transforming Growth Factor-β; TNBS: Trinitrobenzene sulfonic acid; TNF: Tumour Necrosis Factor; UC: Ulcerative colitis; UPR: Unfolded protein response; VEGF: Vascular Endothelial Growth Factor.


    • 1 December 2012
      • Vol. 21  (4) , 349-55

    Common PPARγ variants C161T and Pro12Ala are not associated with inflammatory bowel disease in an Australian cohort.

    by Georgia E Hume, Elizabeth V Fowler, Lyn R Griffiths, James D Doecke, Graham L Radford-Smith

    Peroxisome proliferator-activated receptor (PPAR) γ is a transcription factor, highly expressed in colonic epithelial cells, adipose tissue and macrophages, with an important role in the regulation of inflammatory pathways. The common PPARγ variants C161T and Pro12Ala have recently been associated with Ulcerative Colitis (UC) and an extensive UC phenotype respectively, in a Chinese population. PPARγ Pro12Ala variant homozygotes appear to be protected from the development of Crohn's disease (CD) in European Caucasians. A case-control study was performed for both variants (CD n=575, UC n=306, Controls n=360) using a polymerase chain reaction (PCR)-restriction fragment length polymorphism analysis in an Australian IBD cohort. A transmission disequilibrium test was also performed using CD trios for the PPARγ C161T variant. Genotype-phenotype analyses were also undertaken. There was no significant difference in genotype distribution data or allele frequency between CD and UC patients and controls. There was no difference in allele transmission for the C161T variant. No significant relationship between the variants and disease location was observed. We were unable to replicate in a Caucasian cohort the recent association between PPARγ C161T and UC or between PPARγ Pro12Ala and an extensive UC phenotype in a Chinese population. There are significant ethnic differences in genetic susceptibility to IBD and its phenotypic expression.


  • ACE inhibitors and angiotensin II receptor antagonists in Crohn’s disease management

    by Georgia E Hume, Graham L Radford-Smith

    An increasing repertoire of therapeutic indications for the angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists has followed an explosion of research exploring the role of the proinflammatory and profibrotic renin-angiotensin-aldosterone system in numerous organ systems. This evidence also implicates the renin-angiotensin-aldosterone system in the pathogenesis of other chronic inflammatory and fibrotic disorders, such as Crohn's disease. While the research to date supports this hypothesis, further investigation of the renin-angiotensin-aldosterone system in human Crohn's disease is required before these agents can realistically be investigated in human trials.


  • Novel NOD2 haplotype strengthens the association between TLR4 Asp299gly and Crohnʼs disease in an Australian population

    by Georgia E. Hume, Elizabeth V. Fowler, James Doecke, Lisa A. Simms, Ning Huang, Orazio Palmieri, Lyn R. Griffiths, Timothy H.J. Florin, Vito Annese, Graham L. Radford-Smith

    The first major Crohn's disease (CD) susceptibility gene, NOD2, implicates the innate intestinal immune system and other pattern recognition receptors in the pathogenesis of this chronic, debilitating disorder. These include the Toll-like receptors, specifically TLR4 and TLR5. A variant in the TLR4 gene (A299G) has demonstrated variable association with CD. We aimed to investigate the relationship between TLR4 A299G and TLR5 N392ST, and an Australian inflammatory bowel disease cohort, and to explore the strength of association between TLR4 A299G and CD using global meta-analysis. Cases (CD = 619, ulcerative colitis = 300) and controls (n = 360) were genotyped for TLR4 A299G, TLR5 N392ST, and the 4 major NOD2 mutations. Data were interrogated for case-control analysis prior to and after stratification by NOD2 genotype. Genotype-phenotype relationships were also sought. Meta-analysis was conducted via RevMan. The TLR4 A299G variant allele showed a significant association with CD compared to controls (P = 0.04) and a novel NOD2 haplotype was identified which strengthened this (P = 0.003). Furthermore, we identified that TLR4 A299G was associated with CD limited to the colon (P = 0.02). In the presence of the novel NOD2 haplotype, TLR4 A299G was more strongly associated with colonic disease (P < 0.001) and nonstricturing disease (P = 0.009). A meta-analysis of 11 CD cohorts identified a 1.5-fold increase in risk for the variant TLR4 A299G allele (P < 0.00001). TLR 4 A299G appears to be a significant risk factor for CD, in particular colonic, nonstricturing disease. Furthermore, we identified a novel NOD2 haplotype that strengthens the relationship between TLR4 A299G and these phenotypes.


  • Angiotensinogen and transforming growth factor β1: novel genes in the pathogenesis of Crohn’s disease

    by G E Hume, E V Fowler, D Lincoln, R Eri, D Templeton, T H Florin, J A Cavanaugh, G L Radford-Smith

    Background: Angiotensin peptides may act locally as cytokines in several organ systems with elevated mucosal levels present in Crohn’s disease. A variant in the angiotensinogen gene promoter results in increased peptide production, while transforming growth factor β1 (TGFβ1) codon 25 variants demonstrate variable peptide production, predisposing to fibrosis in several organs. Aims: Conduct an Australian-based analysis of the angiotensinogen-6 variant in two independent inflammatory bowel disease (IBD) cohorts, and examine the role of angiotensinogen-6 and TGFβ1 codon 25 variants in shaping Crohn’s disease phenotype. Methods: IBD Patients (Crohn’s disease = 347, ulcerative colitis = 147) and CD families (n = 148) from two cohorts, together with 185 healthy controls were genotyped for angiotensinogen-6. Genotype-phenotype analyses were performed for both angiotensinogen-6 and TGFβ1 codon 25. Results: Angiotensinogen-6 AA genotype was significantly associated with Crohn's disease (p = 0.007, OR = 2.38, CI = 1.32–4.32) in cohort 1, but not in the smaller cohort 2 (p = 0.19). The association remained significant when the two cohorts were combined (p = 0.008), and in a TDT family analysis (p = 0.03). TGF 1 codon 25 was associated with stricturing Crohn’s disease (p = 0.01, OR = 2.63, CI = 1.16–5.88) and a shorter time to intestinal resection (p = 0.06). Conclusions: The association of the angiotensinogen-6 variant with Crohn’s disease supports a potential role for angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in disease treatment.


  • The Use of Acetic Acid in Magnification Chromocolonoscopy for Pit Pattern Analysis of Small Polyps

    by K. Togashi, D. G. Hewett, D. A. Whitaker, G. E. Hume, L. Francis, M. N. Appleyard

    Background and Study Aims: The role of acetic acid spray during magnification chromocolonoscopy has not previously been evaluated. We aimed to compare the accuracy of predicting polyp histology at magnification colonoscopy, using acetic acid and indigo carmine, either alone or in combination. Patients and Methods: A total of 46 consecutive patients with polyps detected during colonoscopy which measured 10 mm or less were alternately divided into two groups. In group A patients, 1.5 % acetic acid was applied to the mucosa first, followed by indigo carmine spray; in group B patients, the order was reversed. The pit pattern was assessed after application, in real time. All the lesions were resected and examined histologically. Results: Altogether, 37 adenomas and 36 hyperplastic polyps were evaluated. In group A, the diagnostic accuracy after spraying with acetic acid was 95 %, which increased to 98 % after application of indigo carmine. In group B, the accuracy after indigo carmine application was 83 %. After subsequent spraying with acetic acid, images were enhanced in 70 % of patients, with an increase in accuracy to 97 %. The mean time required to obtain an initial clear image with the first dye was 14 seconds for both groups. Conclusions: This is the first description of the use of acetic acid for pit pattern analysis of colonic polyps. Its ease of use, low cost, and safety, together with its excellent accuracy in the assessment of polyp pit patterns suggest that this method could easily be applied to routine magnification colonoscopy.


  • Open Access

    TNFα and IL10 SNPs act together to predict disease behaviour in Crohn’s disease

    by E V Fowler, R Eri, G Hume, S Johnstone, N Pandeya, D Lincoln, D Templeton, G L Radford-Smith

    Background: The cytokines tumour necrosis factor (TNF)α and interleukin (IL)10 have been implicated in the pathogenesis of Crohn’s disease (CD), with increased concentrations reported in patients with active disease. However, limited data exist on their effects on disease phenotype in the same population. Certain single nucleotide polymorphisms (SNPs) within the promoter region of the IL10 (-1082G/A, -592C/A) and TNFα (-308G/A, -857C/T) genes have been associated with altered levels of circulating IL10 and TNFα. Methods: We conducted an Australian based case–control study (304 CD patients; 231 healthy controls) of these four SNPs. Further investigation of two SNPs was conducted using a logistic regression analysis. Results: We identified a possible association of both IL10 SNPs and TNFα-857 with CD. Further investigation of a relationship with disease severity showed a significant association of higher producing IL10-1082G and TNFα-857C alleles with stricturing behaviour, which was strongest when these alleles were combined and persisted after multivariate analysis (p = 0.007; odds ratio (OR) 2.37, 95% CI 1.26 to 4.43). In addition, the TNFα-857CC genotype was independently associated with familial CD (p = 0.03; OR 3.12; 95% CI 1.15 to 8.46). Conclusion: These two SNPs may help to predict disease behaviour in CD patients, which may be clinically useful in shaping treatment of the disease at an earlier stage.